Lytix Biopharma is a biotech company developing novel oncolytic molecules to fight cancer.

Lytix conducts its research and development of drug candidates both in its own R&D department and through partnerships with other organizations. We aspire to continuously strengthen the position of our drug candidates by establishing long-term strategic and value creating collaborations within the pharma and biotech industry as well as with academic institutions.

Lytix’s strategy is to develop drug candidates through clinical phase II, but the company may consider out-licensing or co-development partnerships if appropriate at an earlier stage.

We are committed to alliances, partnerships, and collaborations and will opportunistically evaluate assets that have the potential to expand our pipeline or technological base.

To contact us regarding possible collaboration and partnership, please send an e-mail to bd@lytixbiopharma.com.